Prova Education: Changing the Practice of Medicine

Changing the Practice of Medicine

Discover CME, tools, and guideline-focused education to
improve your knowledge - and patient outcomes.

Screening for Cervical Cancer
Screening for Cervical Cancer
MinuteCE®
Screening for Cervical Cancer
1.00 program credit
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 program credit
Interdisciplinary Management of Gynecologic Cancers
Interdisciplinary Management of Gynecologic Cancers
MinuteCE®
Interdisciplinary Management of Gynecologic Cancers
1.00 program credit
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 program credit
Role of Predictive Biomarkers in Endometrial Cancer
Role of Predictive Biomarkers in Endometrial Cancer
MinuteCE®
Role of Predictive Biomarkers in Endometrial Cancer
1.00 program credit
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 program credit
Applications in Multidisciplinary Care for Cervical Cancer
Applications in Multidisciplinary Care for Cervical Cancer
MinuteCE®
Applications in Multidisciplinary Care for Cervical Cancer
1.00 program credit
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 program credit
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
CME/CE
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
0.50 credits
- Neelam Goyal, MD
- Christyn Edmundson, MD
0.50 credits
Pruritus In PN and AD: Challenge How You Manage Itch
Pruritus In PN and AD: Challenge How You Manage Itch
CME/CE
Pruritus In PN and AD: Challenge How You Manage Itch
1.00 credit
- Peter A. Lio, MD
1.00 credit
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Oncology and Hematology
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Oncology and Hematology
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
- Yungan Tao

CME/CE

Evidence- and Guideline-Based Treatment for High-Risk Locally Advanced Cervical Cancer
Evidence- and Guideline-Based Treatment for High-Risk Locally Advanced Cervical Cancer
MinuteCE®
Evidence- and Guideline-Based Treatment for High-Risk Locally Advanced Cervical Cancer
1.00 program credit
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 program credit
Evidence Base for Treatment Strategies for Endometrial Cancer After Disease Progression and Interdisciplinary Collaboration
Evidence Base for Treatment Strategies for Endometrial Cancer After Disease Progression and Interdisciplinary Collaboration
MinuteCE®
Evidence Base for Treatment Strategies for Endometrial Cancer After Disease Progression and Interdisciplinary Collaboration
1.00 program credit
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 program credit
Evidence- and Guideline-Based Treatment for Advanced/Metastatic Cervical Cancer
Evidence- and Guideline-Based Treatment for Advanced/Metastatic Cervical Cancer
MinuteCE®
Evidence- and Guideline-Based Treatment for Advanced/Metastatic Cervical Cancer
1.00 program credit
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 program credit
MinuteCE®
Innovations in Precision Medicine: Leveraging Guideline-Based Immunotherapy and Targeted Treatments in Gynecologic Oncology
1.00 credit 10 episodes
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 credit 10 episodes
Understanding Endocrine Resistance in HR+/HER2- mBC
Understanding Endocrine Resistance in HR+/HER2- mBC
MinuteCE®
Understanding Endocrine Resistance in HR+/HER2- mBC
0.75 program credits
- Kevin Kalinsky MD, MS
0.75 program credits
PI3K Pathway Inhibition in HR+/HER2- mBC: Mechanistic Insights
PI3K Pathway Inhibition in HR+/HER2- mBC: Mechanistic Insights
MinuteCE®
PI3K Pathway Inhibition in HR+/HER2- mBC: Mechanistic Insights
0.75 program credits
- Komal Jhaveri, MD, FACP
- Kevin Kalinsky MD, MS
0.75 program credits

Clinical Practice

Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Oncology and Hematology
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
- Yungan Tao
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Oncology and Hematology
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
- Prof. Markus Hecht
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
MinuteCE®
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Why CELMoDs Matter in Myeloma
Why CELMoDs Matter in Myeloma
MinuteCE®
Why CELMoDs Matter in Myeloma
1.00 program credit
- Sagar Lonial, MD, FACP
1.00 program credit
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
MinuteCE®
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
1.00 program credit
- Joshua Richter, MD
- Noopur Raje, MD
1.00 program credit
Safety First: Navigating CELMoD-Associated Toxicities
Safety First: Navigating CELMoD-Associated Toxicities
MinuteCE®
Safety First: Navigating CELMoD-Associated Toxicities
1.00 program credit
- Joshua Richter, MD
- Noopur Raje, MD
1.00 program credit

Programs

Managing Immune-Related Adverse Events in Cervical and Endometrial Cancer
Managing Immune-Related Adverse Events in Cervical and Endometrial Cancer
MinuteCE®
Managing Immune-Related Adverse Events in Cervical and Endometrial Cancer
1.00 program credit
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 program credit
Comprehensive Biomarker Testing in mBC Informs Clinical Decision Making
Comprehensive Biomarker Testing in mBC Informs Clinical Decision Making
MinuteCE®
Comprehensive Biomarker Testing in mBC Informs Clinical Decision Making
0.75 program credits
- Komal Jhaveri, MD, FACP
- Kevin Kalinsky MD, MS
0.75 program credits
MinuteCE®
From Pathway to Patient: Clinical Advances in PI3K-Directed Therapy for HR+/HER2- mBC
0.75 credits 8 episodes
- Komal Jhaveri, MD, FACP
- Kevin Kalinsky MD, MS
0.75 credits 8 episodes
The Future of PI3K Inhibition in HR+/HER2- Breast Cancer
The Future of PI3K Inhibition in HR+/HER2- Breast Cancer
MinuteCE®
The Future of PI3K Inhibition in HR+/HER2- Breast Cancer
0.75 program credits
- Komal Jhaveri, MD, FACP
- Kevin Kalinsky MD, MS
0.75 program credits
Triple Threat: Key Data on Simultaneous Estrogen, CDK4/6, and PI3K Inhibition in mBC
Triple Threat: Key Data on Simultaneous Estrogen, CDK4/6, and PI3K Inhibition in mBC
MinuteCE®
Triple Threat: Key Data on Simultaneous Estrogen, CDK4/6, and PI3K Inhibition in mBC
0.75 program credits
- Komal Jhaveri, MD, FACP
- Kevin Kalinsky MD, MS
0.75 program credits
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
MinuteCE®
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
0.50 program credits
- Lauren A. Byers, MD
0.50 program credits

Changing the Practice of Medicine

Popular

CME/CE

Clinical Practice

Programs

Title

Share on ReachMD